Objectives/Hypothesis: Head and neck squamous cell carcinoma (HNSCC) patients who smoke are at risk for poor treatment outcomes. This study evaluated symptom burden and clinical, sociodemographic, and psychosocial factors associated with smoking in surgical patients to identify potential targets for supportive care services.
INTRODUCTION
Tobacco use is an established primary risk factor for head and neck squamous cell carcinoma (HNSCC), [1] [2] [3] and approximately 61,760 new cases of HNSCC and 13, 190 deaths are expected in 2016 in the United States. 4 The 2014 Surgeon General's Report concluded that continued smoking by cancer patients causes adverse outcomes including increased overall and cancer-specific mortality and risk for developing a second primary cancer; continued smoking is also strongly associated with cancer treatment toxicity. 5 HNSCC patients who use tobacco after diagnosis have decreased survival [6] [7] [8] and increased risk for recurrence and development of second cancers. 9, 10 For example, research has demonstrated that continued smoking was associated with decreased survival in 201 p16-positive HNSCC patients treated with laser microdissection, 11 and that smoking during radiotherapy was associated with increased risk of overall and cancer-specific death. 12 Also, as compared with never smokers, former smokers, and HNSCC patients who quit smoking within the past year, current smokers had significantly reduced overall and cancer-specific mortality. 13 The adverse effects of smoking on HNSCC outcomes has implications for the clinical care of HNSCC patients, and as a consequence, a better understanding of the challenges faced by HNSCC patients who smoke at the time of cancer treatment could assist in tailoring treatment and supportive care plans. To enhance patient-centered HNSCC care, it is imperative to consider the unique needs of patients who smoke.
The optimal approach to addressing the adverse effects of smoking in cancer patients is to provide evidence-based cessation support. 14 Patients who smoke and are diagnosed with cancer may be receptive to a "teachable moment," where patients are faced with a life changing diagnosis and may be receptive to making healthy lifestyle changes. 15, 16 Research has examined factors associated with smoking among cancer patients suggesting that continued smokers tend to be younger, female, and unmarried, and have lower levels of education, income, and partner support as well as poorer quality of life and more fatalistic beliefs. [17] [18] [19] [20] [21] [22] However, gaps remain in our understanding of the role of smoking in HNSCC patients' experiences at the time of surgical treatment planning. Developing a better understanding of symptom burden and other patient challenges at the time of diagnosis may guide identification of appropriate supportive care resources and smoking cessation strategies. The purpose of this study was to evaluate the sociodemographic, clinical, psychosocial, and symptomatic factors associated with smoking in HNSCC patients presenting for surgery.
MATERIALS AND METHODS

Participants and Procedures
In a study of adverse surgical outcomes in HNSCC patients, 23 we recruited individuals presenting for surgical management for squamous cell carcinoma of the oral cavity, larynx, or pharynx at two academic cancer centers in the southeastern United States. Participants were excluded if they were younger than age 21 years, not surgical candidates, or had a cognitive impairment that precluded survey completion. Study participants signed informed consent and authorization forms in person following a protocol approved by the institutional review boards of the Medical University of South Carolina and Wake Forest School of Medicine. Participants completed questionnaires by telephone or mail before surgery and received a gift card. The full details of the questionnaire delivery and collection have been reported previously. 23 
Measures
Smoking status. Smoking was assessed with questions from the Tobacco Use Supplement to the Current Population Survey. 24 Participants were asked about lifetime (ever or never) and current (every day, some days, or not at all) cigarette smoking. Former smokers were asked when they started smoking (age) and when they last smoked cigarettes regularly.
Sociodemographic factors. Gender, age, race, marital status, health insurance, years of education, employment status, and financial challenges in the past month were reported.
Clinical factors. Clinical data including cancer site and stage, diagnosis type (new, recurrent/persistent), prior HNSCC treatment, other treatment type (i.e., chemotherapy, radiation), human papillomavirus (HPV) tumor status (positive or negative), and number of comorbid conditions were collected from the electronic medical record at each site using standardized forms.
Psychosocial and behavioral factors. Depression was assessed using the 10-item Center for Epidemiologic Studies Depression Scale, 25, 26 a widely used instrument with excellent properties. Higher scores represent increased depressive symptoms (range, 0-30). Cronbach's a in the study sample was .89.
Fatalism was assessed using five items (1 5 not at all to 5 5 extremely) adapted from previous research 27, 28 ; higher scores reflected more fatalistic beliefs (range, 1-5; Cronbach's a 5 .72).
Religiosity was assessed using the Santa Clara Strength of Religious Faith instrument. 29 Participants rated their agreement with five statements concerning faith (1 5 strongly disagree to 6 5 strongly agree). Higher scores reflected higher strength of religious faith (range, 5-30; Cronbach's a 5 .95).
We also assessed alcohol use (current use and binge drinking, which was defined as consuming 4 or 5 drinks on one occasion for women and men, respectively).
Symptoms. The head and neck cancer module of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire 30, 31 was used to assess symptoms. We assessed problems with pain, swallowing, senses (i.e., taste/smell), speech, social eating, social contact (i.e., appearance), teeth, opening mouth, dry mouth, sticky saliva, and cough over the past week (1 5 not at all to 4 5 very much). Also, we examined whether participants felt ill and used pain killers, nutritional supplements, or a feeding tube and whether they lost or gained weight in the past week. Scores ranged from 0 to 100; higher scores reflected worse problems.
Data Analysis
Descriptive statistics were used to summarize sociodemographic and clinical characteristics. Participants were categorized as never smokers if they had not smoked at least 100 cigarettes in their lifetime, and former smokers if they had smoked at least 100 cigarettes in their lifetime but successfully stopped smoking at least 6 months prior to enrollment. Patients were defined as current/recent smokers if they reported currently smoking or having quit 6 months prior to enrollment. Current smokers were combined with those who had quit within the past 6 months a priori; this cutoff was set because this group is at high risk of relapse 32 and because patients who quit smoking within the past year are at high risk for misrepresenting tobacco use. 33, 34 Therefore, combining current smoking and recent quitting provides a conservative estimate of the associations between smoking and other variables. We compared sociodemographic (age, gender, race, education, marital status, monthly financial challenges, health insurance type, employment status), clinical (cancer site/stage, diagnosis type (new, recurrent/persistent), prior HNSCC treatment, comorbid conditions), psychosocial and behavioral (depression, fatalism, religiosity, alcohol use), and symptom factors in current/recent, former, and never smokers using Kruskal-Wallis and Fisher exact tests for tests for continuous and categorical variables, respectively. Pairwise comparisons (current/recent smokers vs. both former and never smokers) followed when overall tests were significant (a 5 .10). Multiple linear regression models controlling for sociodemographic and clinical factors were used to further examine symptoms associated with smoking status. Covariates we considered included factors hypothesized a priori to be associated with symptom burden including age, gender, race, health insurance, cancer stage, prior head and neck cancer treatment, and comorbid conditions. For each model, these covariates were retained if they were significant (a 5 .10) in the presence of other covariates. Model refinement was performed by including all significant covariates in simple models and then successively removing the least significant covariate until all covariates in the model were significant (P .10).
RESULTS
One hundred fifty-four patients met inclusion criteria, and 120 (78%) consented and were enrolled. One hundred three patients (86% of enrolled) completed questionnaires. Most participants were Caucasian males, and over one-half had stage IV cancer (Table I) . Seventeen percent of participants had HPV-positive tumors, and in addition to surgery, 41% of participants also had chemotherapy and 56% also had radiation. The majority of participants (78%) had a cigarette smoking history. Of these, 27% were current smokers, 14% quit within the past 6 months, and 37% quit greater than 6 months ago. Current/recent smokers had smoked an average of 40.2 years (standard deviation [SD] 5 9.5 years), whereas former smokers had smoked an average of 31.0 years (SD 5 13.1 years). Among former smokers, the average time since quitting was 14.1 years (SD 5 10.1 years).
Smoking Status and Demographic, Clinical, and Psychosocial Factors
Smoking status (current/recent, former, never) was significantly associated with employment status, health insurance, and financial challenges and marginally associated with marital status (Table I) . Subsequent pairwise comparisons showed that current/recent smokers were less likely than former smokers to be partnered (P 5 .03) and more likely to lack adequate finances to meet monthly expenses (P 5 .001). Current/recent smokers were also more likely than both former and never smokers to be unemployed (both P 5.02) and have no health insurance (P 5.04 and P 5 .02, respectively).
Smoking status was associated with diagnosis type andcomorbid health conditions (Table I) . Pairwise comparisons showed that former smokers were more likely to have recurrent/persistent disease (P 5 .003) and more comorbid conditions (P 5 .02) than current/recent smokers.
Depression did not differ by smoking status, but fatalism and religiosity were marginally associated with smoking. Pairwise comparisons showed that current/ recent smokers had higher fatalistic beliefs compared with never smokers (P 5 .03), and never smokers reported stronger religious faith than current/recent smokers (P 5 .04). Current alcohol use was not associated with smoking status, but binge drinking was, with pairwise comparisons showing that this behavior was more prevalent in current/recent smokers compared with never smokers (P 5 .006).
Smoking Status and Symptoms
As shown in Figure 1 , smoking status was significantly associated with multiple head and neck cancerspecific symptoms (7/17 [41%] of the symptoms assessed). For all symptoms except problems opening mouth, current/recent smokers reported worse symptoms than never smokers. Pairwise comparisons showed that current/recent smokers were more likely than never smokers to have used pain killers (P 5 .01) and report feeling ill (P 5 .005) over the past week and to have problems with cough (P 5 .03), social contact (P 5 .004), social eating (P 5 .03), speech (P 5 .005), sense of taste/ smell (P 5.005), and swallowing (P 5 .005). Current/ recent smokers were also more likely than both former and never smokers to report weight loss over the past week (P 5.03 and P 5 .01, respectively).
Adjusted Regression Models
Adjusted regression models further examining head and neck cancer-specific symptoms significantly associated with smoking status are shown in Table II . Controlling for potential covariates (age, gender, race, health insurance status, comorbid health conditions, cancer stage, and prior HNC treatment), with P .10, smoking status remained significantly associated with problems with swallowing, speech, appearance, cough, feeling ill, and weight loss (all P < .05). Specifically, these models highlighted that current/recent smokers reported increased swallowing problems compared to former smokers (P 5 .04), an association that became even more pronounced compared to never smokers (P < .01). A similar pattern was seen for problems with speech, with current/recent smokers reporting more problems than former smokers (P 5 .03) and even more problems when compared to never smokers (P <.01). Current/recent smokers were also more likely to report elevated levels of problems with cough than both former and never smokers (P < .01 and P 5 .02, respectively). Lastly, current/recent smokers were more likely to report weight loss (P 5 .01), feeling ill (P 5.02), and problems with social contact (P 5 .01) when compared to never smokers with the highest difference seen in weight loss.
DISCUSSION
This study highlighted that current-and recentsmoking HNSCC patients had a higher symptom burden and a profile consistent with fewer social, economic, and psychological resources than former and never smokers. Results provide insight into the factors associated with smoking in HNSCC patients presenting for surgical management, a promising smoking cessation opportunity. 35 The 2014 Surgeon General's Report confirmed the adverse effects of smoking on cancer patients and survivors across virtually all cancer disease sites, 5 and numerous reviews have emphasized the need to address tobacco use in cancer patients to improve clinical treatment outcomes. 36, 37 Smoking cessation is now advocated as a clinical standard of care by several organizations including the American Society for Clinical Oncology 38 and the American Association for Cancer Research. 39 The National Comprehensive Cancer Network created new evidence-based guidelines in 2015 for smoking cessation support for all patients who report smoking within the past 30 days. 40 However, what is lacking in many of these guidelines is a tailored approach to the clinical, sociodemographic, psychosocial, and symptomatic factors associated with current smoking in cancer patients. Patient-centered care may be enhanced with provision of evidence-based smoking cessation support in combination with targeting at-risk factors associated with smoking that may affect treatment outcomes.
Consistent with prior research in the general population 5 and with cancer patients, 17, 18, 21, 22 our findings confirm that HNSCC surgical patients who are current or recent smokers can be characterized as a more marginalized group facing increased challenges (e.g., more likely to be unpartnered, unemployed, lacking insurance, and have inadequate finances). The diminished availability of financial resources and the potential implications of educational and support needs for HNC smokers suggests the need for heightened awareness and attention to these challenges prior to treatment and consideration of interventions. Importantly, smokers may also have fewer psychological resources (e.g., lower religious faith 41 and higher fatalistic beliefs 20 ) to cope with Findings are significant at the P .05 level. ‡ All models examined smoking status (former smokers vs. current/recent smokers and never smokers vs. current/recent smokers) as a predictor of symptoms controlling for age, gender, race, health insurance (any or none), comorbidities (any or none), previous head and neck cancer treatment (yes or no), and cancer stage; a stepwise approach was used with covariates with P .10 dropped for final models.
surgical challenges and recovery and engage more frequently in risky health behaviors such as binge drinking. 22 This study demonstrated that HNSCC patients who report current/recent smoking had a higher symptom burden when compared to former and never smokers. Current/recent smokers reported greater severity in nine of 17 symptoms assessed, and in no case did never smokers report significantly greater severity than current/ recent smokers. In adjusted models controlling for clinical factors that may impact symptom burden (e.g., cancer stage, previous treatment), current/recent smokers consistently reported more problems with swallowing, speech, and cough, with the most severe symptoms reported by current/recent smokers followed by former and then never smokers. In adjusted models, current/ recent smokers were also more likely than never smokers to report problems with social contact, feeling ill, and weight loss. Consistent with our findings, Jensen and colleagues 42 found continued smoking after HNSCC treatment was associated with worse swallowing, cough, and weight loss problems, and also found that smokers had more problems with other symptoms (pain, sense of smell/taste, dry mouth, use of feeding tube, and nutritional supplements). Other studies have also shown that pain 43 was worse in smoking HNSCC patients compared to nonsmokers. The additional symptom differences found in the Jensen et al. study could be because this study was conducted after treatment when symptoms can escalate. 40 Of note, our sample size may have limited our ability to detect differences as we observed that several symptoms, although not significantly different, were higher in smokers than others. Collectively, findings suggest that evaluating these symptoms in HNSCC patients who are current smokers may be important to mitigating adverse outcomes. However, this hypothesis will require future testing, as this study did not evaluate whether treating these symptoms in smokers affected clinical outcomes.
Interestingly, we observed that former smokers presented with more comorbid conditions and greater rates of recurrent/persistent disease than current/recent smokers. This is an intriguing finding because continued smoking predisposes patients to a broad spectrum of adverse health conditions. 5 Although more research is needed to identify whether this clinical burden among former smokers relates to other tobacco, health, or demographic factors, this observation highlights that former smokers may need resources to cope with the challenges of disease recurrence and management of other conditions during treatment.
Results did not support an association between smoking and depression, in contrast to previous research. 20, 44, 45 This could be because the majority of participants had high depression, in contrast to the other studies mostly conducted after treatment when psychological functioning tends to improve. It is critical to consider best practices for monitoring depression during treatment, because HNSCC patients demonstrate high levels of depression, 46 and promising work has emphasized the benefits of addressing smoking and depression simultaneously in HNC. 18, 47 Overall, this study highlights that HNSCC patients who report current/recent smoking may present with higher symptom burden and several additional sociodemographic, clinical, and psychosocial challenges that may place them at an overall disadvantage as compared with former and never smokers. These findings argue for routine assessment of smoking status, symptom burden, and other factors at diagnosis within the HNSCC setting. Unfortunately, most oncologists readily assess tobacco use but do not provide cessation support 48, 49 due to a lack of time, resources, and education. 50 The authors are unaware of studies evaluating practice patterns associated with smoking cessation support combined with management of symptoms and other sociodemographic and psychosocial challenges. However, combining smoking cessation with routine screening and supportive care referrals (e.g., social work, counseling) to address financial (e.g., housing, nutrition, transportation) and symptom management needs may benefit these at-risk patients.
Strengths of this study include our exploration of multiple patient characteristics in relation to smoking status to allow a consideration of the whole patient. However, this was also a limitation given our sample size, and the statistical significance of any one association needs to be interpreted with caution; instead the focus should be on the consistent pattern of findings observed. For our models, we were limited in the number of covariates we could select due to our modest sample size. Therefore, this provides a preliminary look at the relationships between symptom burden and smoking status, and future studies should further examine the role of other clinical and smoking characteristics in symptom burden. This study was also cross-sectional, and results should be replicated in the future. Also, although the parent study from which this analysis was conducted 23, 51 used biochemical verification of smoking on the day of surgery, we used self-reported smoking before surgery. Despite study limitations, strengths include the sample's demographic and clinical diversity and the use of validated instruments.
CONCLUSION
Current-and recent-smoking HNSCC patients may be disadvantaged in multiple ways and have a higher symptom burden when compared to former and never smokers before surgery. Limited social, economic, and psychological resources should be considered when planning HNSCC care in patients who are current or recent smokers. Future studies should explore the potential benefits of comprehensively addressing smoking cessation needs as well as symptoms in smokers at clinic presentation to examine whether addressing both can have a meaningful effect on cancer treatment outcomes.
